SCHEMBL484247

SCHEMBL484247

FCCOCCOCCn1c(Br)nc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
MAPK1 P28482 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
ATM Q13315 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 1/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
HRH1 P35367 1/20 0.44
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30897383 0.86 KDM4E (0.62) POLBMAPK1SMN1; SMN2ATML3MBTL1
SCHEMBL484087 0.83 CXCR4 (0.46) POLBMAPK1KMT2AMEN1LMNA
SCHEMBL18046824 0.79 HPGD (0.64) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL30897384 0.75 SMN1; SMN2 (0.47) POLBMAPK1SMN1; SMN2ATML3MBTL1
SCHEMBL12468122 0.74 KDM4E (0.58) POLBMAPK1SMN1; SMN2ATML3MBTL1
SCHEMBL12468168 0.74 KDM4E (0.62) POLBMAPK1SMN1; SMN2KMT2AMEN1
SCHEMBL16855623 0.73 POLB (0.65) POLBSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL12402793 0.71 APP (0.54) POLBMAPK1SMN1; SMN2ATML3MBTL1
SCHEMBL12324075 0.71 APP (0.53) POLBMAPK1SMN1; SMN2ATML3MBTL1
SCHEMBL230441 0.70 HTT (0.62) POLBMAPK1SMN1; SMN2L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411057-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2020-05-06 EP disclosed
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders LILLY CO ELI (US) 2013-11-14 US disclosed
US-8491869-B2 Imaging agents for detecting neurological disorders ELI LILLY AND COMPANY (US) 2013-07-23 US disclosed
EP-2411057-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS Siemens Medical Solutions USA, Inc. (US) 2012-02-01 EP disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
WO-2010111303-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-30 WO disclosed
US-20100239496-A1 Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 POLB 3035/4885MAPK1 1578/4885SMN1; SMN2 39/4885
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 POLB 2199/4885MAPK1 2979/4885SMN1; SMN2 26/4885
US-20100239496-A1 Imaging agents for detecting neurological disorders MAPT, APP, PSEN1 POLB 3035/4885MAPK1 1578/4885SMN1; SMN2 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.